References
- Ginarte M, Pereiro M, Toribio J. Cutaneous polyarteritis nodosa in a child. Pediatr Dermatol. 1998;15:103–7.
- Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936–41.
- Balbir-Gurman A, Nahir AM, Braun-Moscovici Y. Intravenous immunoglobulins in polyarteritis nodosa restricted to the limbs: case reports and review of the literature. Clin Exp Rheumatol. 2007; 25(1 suppl 44):S28–30.
- Khellaf M, Hamidou M, Pagnoux C, Michel M, Brisseau JM, Chevallier X, et al. Vasculitis restricted to the lower limbs: a clinical and histopathological study. Ann Rheum Dis. 2007;66:554–6.
- Garcia-Porrua C, Mate A, Duran-Mariño JL, Fernandez-Martinez C, Gonzalez-Gay MA. Localized vasculitis in the calf mimicking deep venous thrombosis. Rheumatology (Oxford). 2002;41:944–5.
- Borrie P. Cutaneous polyarteritis nodosa. Br J Dermatol. 1972;87: 87–95.
- Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol. 2003;21:241–8.
- Lee HH, Song IH, Friedrich A, Gauliard J, Röwert J. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists. Brit J Dermatol. 2007;156:486–91.
- Kumar L, Thapa BR, Sarkar B, Walia BN. Benign cutaneous polyarteritis nodosa in children below 10 years of age—a clinical experience. Ann Rheum Dis. 1995;54:134–6.
- Daoud MS, Hutton KP, Gibson LE. Cutaneous periarteritis nodosa: a clinicopathological study of 79 cases. Br J Dermatol. 1997;136: 706–13.
- Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant-cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041–8.
- Coll-Vinent B, Vilardell C, Font C, Oristrell J, Hernández-Rodríguez J, Yagüe J, et al. Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis. 1999;58:189–92.
- Hernández-Rodríguez J, García-Martínez A, Casademont J, Filella X, Esteban MJ, López-Soto A, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum. 2002;47:29–35.
- Dewar CL, Bellamy N. Necrotizing mesenteric vasculitis after longstanding cutaneous polyarteritis nodosa. J Rheumatol. 1992;19: 1308–11.
- Till SH, Amos RS. Long-term follow-up of juvenile-onset cutaneous polyarteritis nodosa associated with streptococcal infection. Br J Rheumatol. 1997;36:909–11.
- Feinstein J, Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Rheumatol. 2005 Jul, 32(7), pp. 1371–3. J Clin Rheumatol. 2005;11(4):219–22.
- Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford). 2009;48(8):978–86. (Epub 2009 Jun 17).